Filing Details
Oruka Therapeutics, Inc. (NASDAQ:ORKA) filed a Form 8-K with the Securities and Exchange Commission on October 26, 2026, disclosing a material event.
8k filedNASDAQ:ORKA
Oruka Therapeutics, Inc. (ORKA) Reports Material Event to SEC
Oruka Therapeutics, Inc. (NASDAQ:ORKA) filed a Form 8-K with the Securities and Exchange Commission on October 26, 2026, disclosing a material event.
At publication ·
What changed
Oruka Therapeutics, Inc. (NASDAQ:ORKA) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Oruka Therapeutics filed a Form 8-K with the SEC on October 26, 2026, disclosing a material event requiring shareholder awareness.
- The healthcare company's stock trades at $90.33 with a market capitalization of $1.1 billion.
- Form 8-K filings report significant events such as leadership changes, material agreements, acquisitions, or asset sales between regular reports.
Market Context
Oruka Therapeutics, Inc.'s stock currently trades at $90.33 with a market capitalization of $1.1B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Oruka Therapeutics, Inc.'s stock.
All SEC filings for Oruka Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View ORKA Stock Page
Frequently Asked Questions
Where can I read ORKA's SEC filings?
Browse all filings on our ORKA SEC filings page.
What types of SEC filings does Oruka Therapeutics, Inc. file?
Public companies like Oruka Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.